EFFECTIVENESS OF VITAMIN-LIKE SUBSTANCES IN COMPLEX THERAPY OF DIABETES MELLITUS AND ITS COMPLICATIONS: A COMPREHENSIVE LITERATURE REVIEW

UDC 616.379-008.64:615.356

Authors

  • Veronika O. Krasyukova Altai State Medical University, Barnaul Email: 922kvo@mail.ru
  • Tatiana G. Semenyuk Altai State Medical University, Barnaul Email: brn.tgs@mail.ru
  • Vyacheslav M. Vdovin Altai State Medical University, Barnaul Email: erytrab@gmail.com

DOI:

https://doi.org/10.31684/25418475-2023-2-106

Keywords:

diabetes mellitus, vitamin-like substances, complications of diabetes mellitus

Abstract

The review of the scientific literature examines the relevance of the use of vitamin-like substances (coenzyme Q10, lipoic acid, taurine, inositol, pyrroloquinolinquinone) in diabetes mellitus, which is a common chronic disease that causes early disability and mortality in patients. The increase in the incidence of diabetes leads to the search for new ways of complex treatment of both the disease itself and its complications. Currently, new nutraceuticals undergo a thorough examination under strict evidence-based medicine, which is a guarantee of their effectiveness and safety. The authors, based on experimental data and the results of clinical studies presented in the open literature, demonstrated the positive effect of the use of vitamin-like substances for the treatment of diabetes mellitus and the prevention of its complications.

Downloads

Download data is not yet available.

Author information

Veronika O. Krasyukova,
Altai State Medical University, Barnaul

Senior Lecturer, Department of Pathological Physiology, Altai State Medical University, Barnaul.
E-mail: 922kvo@mail.ru Tel.: 8-913-216-2185
E-library SPIN: 6968-3925, https://orсid.org/0000-0001-5752-3003
Researcher ID: ABB-8780-2021

Tatiana G. Semenyuk,
Altai State Medical University, Barnaul

Senior Lecturer, Department of Pathological Physiology, Altai State Medical University, Barnaul. E-mail: brn.tgs@mail.ru
E-library SPIN: 3650-5176, https://orсid огсіԁ.org/0000-0002-7185-0585

Vyacheslav M. Vdovin,
Altai State Medical University, Barnaul

Cand. Sci. (Med.), Associate Professor, Head of Pathological Physiology Department, Altai State Medical University, Barnaul.
E-mail: erytrab@gmail.com
E-library SPIN: 5885-4504, https://orсid.org/0000-0002-4606-3627,
Researcher ID: B-4400-2019

References

  • Yagudina R.I., Kulikov A.Yu., Arinina E.E. Pharmacoeconomics of type 2 diabetes mellitus. Moscow: Meditsinskoe informatsionnoe agentstvo, 2011.352. (In Russ.)
  • King H. WHO and the International Diabetes Federation: regional partners. Bull World Health Organ. 1999; 77(12): 954.
  • Neel J. V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 1962. Bull World Health Organ. 1999; 77(8): 694–693.
  • King H., Roglic G. Diabetes and the "thrifty genotype": Commentary. Bull World Health Organ. 1999; 77(8): 692–693.
  • White F., Nanan D. Status of national diabetes programmes in the Americas. Bull World Health Organ. 1999; 77(12): 981–987.
  • International Diabetes Federation: Diabetes Atlas, 2021.
  • Blonde L., Umpierrez G.E., Reddy S.S., McGill J.B., Berga S.L., Bush M., Chandrasekaran S., DeFronzo R. A., Einhorn D., Galindo R. J., Gardner T. W., Garg R., Garvey W.T., Hirsch I.B., Hurley D.L., Izuora K., Kosiborod M., Olson D., Patel S.B., Pop-Busui R., Sadhu A.R., Samson S.L., Stec C., Tamborlane Jr. W.V., Tuttle K.R., Twining C., Vella A., Vellanki P., Weber S.L. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice. 2022; 28(10): 923-1049. https://doi.org/10.1016/j.eprac.2022.08.002
  • Ametov A.S. Diabetes mellitus type 2. Problems and solutions. Moscow: GEOTAR-Media, 2011. 704. (In Russ.).
  • Caro J.J., Ward A.J., Judith A., O’Brien. Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S. Diabetes Care. 2002; 25:476-481. https://doi.org/10.2337/diacare.25.3.476.
  • Kevra M.K., Sidenko V.M., Kevra Zh.S. Vitamin-like water-soluble substances. Medicinskie znaniya. 2020; 5: 19-25. (In Russ.).
  • Kalen A., Appelkvist E.L., Dallner G., Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989; 24:579-584.
  • Ametov A.S, Solov'eva O.L. Oxidative stress in type 2 diabetes mellitus and methods for its correction. Problemy Endokrinologii. 2011; 57(6): 52‑56. (In Russ.).
  • Thomas S.R., Neuzil J., Stocker R. Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler Thromb Vasc Biol. 1996; 16(5):687-96. https://doi.org/10.1161/01.atv.16.5.687.
  • Zaharova I.N., Obynochnaya E.G., Skorobogatova E.V., Malashina O.A. Influence of an antioxidant based on ubiquinone on the activity of lipid peroxidation and antioxidant protection in pyelonephritis in children. Pediatria. 2005; 4: 75-78. (In Russ.).
  • Soderberg M., Edlund C., Kristensson K., Dallner G., Lipid composition of different regions of the human brain during aging. J Neurochem. 1990; 54: 415-423.
  • Raygan F., Rezavandi Z., Tehrani S.D., Farrokhian A., Asemi Z. The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome. Eur J Nutr. 2016; 55(8):2357-2364. https://doi.org/10.1007/s00394-015-1042-7.
  • Sun I.O., Jin L., Jin J., Lim S.W., Chung B.H., Yang C.W. The effects of addition of coenzyme Q10 to metformin on sirolimus-induced diabetes mellitus. Korean J Intern Med. 2019; 34(2): 365-374. https://doi.org/10.3904/kjim.2017.004.
  • Samimi M., Zarezade Mehrizi M., Foroozanfard F., Akbari H., Jamilian M., Ahmadi S., Asemi Z. The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2017; 86(4): 560-566. https://doi.org/10.1111/cen.13288.
  • McCarty M.F. Can correction of sub-optimal coenzyme Q status improve cell function in type II diabetics? Medical Hypotheses. 1999; 52:397-400.
  • Tyukalova L.A., Lukyanova М.А. Cognitive impairment treatment in arterial hypertension with diabetes mellitus 2nd type. Russ J Cardiol 2015; 2(118): 95–99. (In Russ.) http://dx.doi.org/10.15829/1560-4071-2015-02-95-99.
  • Hayder M. Al-Kuraishy, Ali I Al-Gareeb, Hala A Shams, Farah Al-Mamorri. Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus. J Lab Physicians. 2019; 11(4):317-322. http://doi:10.4103/JLP.JLP_123_19.
  • Watts G.F., Playford D.A., Croft K.D., Ward N.C., Mori T.A., Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia. 2002; 45(3):420-6. http://doi.org/10.1007/s00125-001-0760-y.
  • Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress activated signaling pathways: a unifying hypothesis of type 2 diabete. Endocr. Rev. 2002; 23:599-622.
  • Diesel B., Kulhanek-Heinze S., Höltje M., Brandt B., Höltje H.-D., Vollmar A. M., Kiemer A. K. Alpha-lipoic acid as a directly binding activator of the insulin receptor: protection from hepatocyte apoptosis. Biochemistry. 2007; 46(8): 2146-55. http://doi.org/10.1021/bi602547m.
  • Wang Y., Li X., Guo Y., Chan L., Guan X. Alpha-Lipoic acid increases energy expenditure by enhancing adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling in the skeletal muscle of aged mice. Metabolism. 2010; 59(7): 967-76. http://doi.org/10.1016/j.metabol.2009.10.018.
  • Melhem M.F., Craven P.A., Liachenko J., DeRubertis F.R. Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol. 2002; 13(1): 108-116. http://doi.org/10.1681/ASN.V131108.
  • Akbari M., Ostadmohammadi V., Lankarani K.B., Tabrizi R., Kolahdooz F., Khatibi S.R., Asemi Z. The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: A systematic review and meta-analysis of randomized controlled trials. Meta-Analysis Metabolism. 2018; 87: 56-69. http://doi.org/10.1016/j.metabol.2018.07.002.
  • Heitzer T., Finckh B., Albers S., Krohn K., Kohlschütter A., Meinertz T. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med. 2001; 31(1): 53-61. http://doi.org/10.1016/s0891-5849(01)00551-2.
  • Mijnhout G.S., Kollen B.J., Alkhalaf A., Kleefstra N., Bilo HJ.G. Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012; 2012(2952): 456279. http://doi.org/10.1155/2012/456279.
  • Sola S., Mir MQ.S., Cheema FA., Khan-Merchant N., Menon R.G., Parthasarathy S., Khan B.V. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005; 111(3): 343-8. http://doi.org/10.1161/01.CIR.0000153272.48711.B9
  • Ziegler D., Schatz H., Conrad F., Gries F. A., Ulrich H., Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997; 20(3): 369-73. http://doi.org/10.2337/diacare.20.3.369.
  • Gębka A., Serkies-Minuth E., Raczyńska D. Effect of the administration of alpha-lipoic acid on contrast sensitivity in patients with type 1 and type 2 diabetes. Mediators Inflamm. 2014; 2014: 131538. http://doi.org/10.1155/2014/131538.
  • Schaffer S., Kim H.W. Effects and Mechanisms of Taurine as a Therapeutic Agent. Biomol Ther (Seoul). 2018; 26(3): 225-241. http://doi.org/10.4062/biomolther.2017.251.
  • Sagara M., Murakami S., Mizushima S., Liu L., Mori M., Ikeda K., Nara Y., Yamori Y. Taurine in 24-h Urine Samples Is Inversely Related to Cardiovascular Risks of Middle Aged Subjects in 50 Populations of the World. Medicine Advances in experimental medicine and biology. 2015; 803: 623-636. http://doi.org/10.1007/978-3-319-15126-7_50.
  • Yamori Y., Taguchi T., Hamada A., Kunimasa K., Mori H., Mori M. Taurine in health and diseases: consistent evidence from experimental and epidemiological studies. J Biomed Sci. 2010; 17(S1): S6. http://doi.org/10.1186/1423-0127-17-S1-S6.
  • Nandhini A.T.A., Thirunavukkarasu V., Anuradha C. V. Taurine modifies insulin signaling enzymes in the fructose-fed insulin resistant rats. Diabetes Metab. 2005; 31(4): 337-44. http://doi.org/10.1016/s1262-3636(07)70202-1.
  • Koh J.H., Lee E.S., Hyun M., Kim H.M., Choi Y.J., Lee E.Y., Yadav D., Chung C.H. Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model. Int J Endocrinol. 2014; 2014: 397307. http://doi.org/10.1155/2014/397307.
  • Nandhini A.T.A., Thirunavukkarasu V., Anuradha C.V. Taurine prevents collagen abnormalities in high fructose-fed rats. Indian J Med Res. 2005; 122(2): 171-7.
  • Mikami N., Hosokawa M., Miyashita K. Dietary combination of fish oil and taurine decreases fat accumulation and ameliorates blood glucose levels in type 2 diabetic/obese KK-A(y) mice. J Food Sci. 2012; 77(6): 114-20. http://doi.org/10.1111/j.1750-3841.2012.02687.x.
  • Trachtman H., Futterweit S., Maesaka J., Ma C., Valderrama E., Fuchs A., Tarectecan A.A. Rao P.S., Sturman J.A., Boles T.H., et al. Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats. The American journal of physiology. 1995; 269(3): 429-38. http://doi.org/ 10.1152/ajprenal.1995.269.3.F429.
  • Ito T., Schaffer S., Azuma J. The effect of taurine on chronic heart failure: actions of taurine against catecholamine and angiotensin II. Amino Acids. 2014; 46(1): 111-9. http://doi.org/10.1007/s00726-013-1507-z.
  • Ito T., Schaffer S.W., Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids. 2012; 42(5): 1529-39. http://doi.org/10.1007/s00726-011-0883-5.
  • Limanova O.A., Gromova O.A., Torshin I.Yu., Gromov A.N., Grishina T.R. Systematic analysis of molecular mechanisms and physiological effects of myo-inositol: findings of molecular biology, experimental and clinical medicine. Effektivnaya farmakoterapiya. 2013; 28: 32-41. (In Russ.).
  • Miñambres I., Cuixart G., Gonçalves A., Corcoy R. Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2019; 38(3): 1146-1152. http://doi.org/10.1016/j.clnu.2018.06.957.
  • Corrado F., D'Anna R., Di Vieste G., Giordano D., Pintaudi B., Santamaria A., Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011; 28(8): 972-5. http://doi.org/10.1111/j.1464-5491.2011.03284.x.
  • Fruzzetti F., Perini D., Russo M., Bucci F., Gadducci A. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017; 33(1): 39-42. http://doi.org/10.1080/09513590.2016.1236078.
  • Tagliaferri V., Romualdi D., Immediata V., De Cicco S., Di Florio C., Lanzone A., Guido M. Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol (Oxf). 2017; 86(5): 725-730. http://doi.org/10.1111/cen.13304.
  • Hong J.H., Jang H.W., Kang Y.E., Lee J.H., Kim K.S., Kim H.J., Park K.R., Ku B. J. Urinary chiro- and myo-inositol levels as a biological marker for type 2 diabetes mellitus. Dis Markers. 2012; 33(4): 193-9. https://doi.org/10.1155/2012/734718.
  • Naveed M, Tariq K, Sadia H, et al. The life history of pyrroloquinoline quinone (PQQ): a versatile molecule with novel impacts on living systems. Int J Mol Biol Open Access. 2016; 1(1): 29-46. http://doi.org/10.15406/ijmboa.2016.01.00005.
  • Murray M. Pyrroloquinoline quinone (PQQ): the next essential nutrient and supplement superstar. Nutrafoods. 2018; 17: 125-129. http://doi.org/10.17470/NF-018-1013-3.
  • Misra, H.S., Rajpurohit, Y.S., Khairnar, N.P. Pyrroloquinoline-quinone and its versatile roles in biological processes. Journal of Biosciences. 2012; 37: 313-325. http://dx.doi.org/10.1007/s12038-012-9195-5
  • Akagawa M., Nakano M., Ikemoto K. Recent progress in studies on the health benefits of pyrroloquinoline quinone. Biosci Biotechnol Biochem. 2016; 80(1): 13-22. http://doi:10.1080/09168451.2015.1062715.
  • Bauerly K., Harris C., Chowanadisai W., Graham J., Havel P. J., Tchaparian E., Satre M., Karliner J.S., Rucker R.B. Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats. PLoS One. 2011; 6(7): e21779. http://doi.org/10.1371/journal.pone.0021779.
  • Takada M., Sumi M., Maeda A., Watanabe F., Kamiya T., Ishii T., Nakano M., Akagawa M. Pyrroloquinoline quinone, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves impaired glucose tolerance in diabetic KK-A(y) mice. Biochem Biophys Res Commun. 2012; 428(2): 315-20. http://doi.org/10.1016/j.bbrc.2012.10.055.
  • Jonscher K.R., Stewart M.S., Alfonso-Garcia A., DeFelice B.C., Wang X.X., Luo Y., Levi M., Heerwagen M.J.R., Janssen R.C., A de la Houssaye B., Wiitala E., Florey G., Jonscher R.L., Potma E.O., Fiehn O., Friedman J.E. Early PQQ supplementation has persistent long-term protective effects on developmental programming of hepatic lipotoxicity and inflammation in obese mice. FASEB J. 2017; 31(4): 1434-1448. http://doi.org/10.1096/fj.201600906R.

    • Downloads

    Published

    2023-06-26

    How to Cite

    Krasyukova V. O., Semenyuk T. G., Vdovin V. M. EFFECTIVENESS OF VITAMIN-LIKE SUBSTANCES IN COMPLEX THERAPY OF DIABETES MELLITUS AND ITS COMPLICATIONS: A COMPREHENSIVE LITERATURE REVIEW: UDC 616.379-008.64:615.356 // Bulletin of Medical Science, 2023. Vol. 30, № 2. P. 106–115 DOI: 10.31684/25418475-2023-2-106. URL: https://newbmn.asmu.ru/bmn/article/view/577.

    Issue

    Vol. 30 No. 2 (2023): Bulletin of Medical Science

    Section

    REVIEWS

    License

    Copyright (c) 2023 Вероника Олеговна Красюкова, Татьяна Геннадьевна Семенюк, Вячеслав Михайлович Вдовин

    Creative Commons License

    This work is licensed under a Creative Commons Attribution 4.0 International License.